Upstream / Downstream


Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, November 30th.

Thank you for your patience.

To Purchase # 8915LC

8915LC 10 µg (With Carrier) $199.00
8915LF 10 µg (Carrier Free) $199.00


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


Source / Purification

Recombinant human TGF-β1 (hTGF-β1) Ala279-Ser390 (Accession #P01137) was expressed in human 293 cells at Cell Signaling Technology.

Product Description


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β1. Less than 1% migrates as monomer hTGF-β1 under non-reduced (-) conditions. All lots are greater than 98% pure.

Molecular Formula:

Recombinant hTGF-β1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,794. DTT-reduced protein migrates as a 13 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 25 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β1 was verified by amino acid sequencing.


The bioactivity of recombinant hTGF-β1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.04-0.20 ng/ml.


Less than 0.01 ng endotoxin/1 μg hTGF-β1.

Product Usage Information


With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-β1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-β1 activities include proliferation, angiogenesis and promotion or inhibition of many immune events (1-3). TGF-β1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGF-β1 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,4). The oligomeric receptor complex phosphorylates subsets of the SMAD proteins that then act to induce and repress a number of target genes (1,3,4). TGF-β1 binding can also activate the Erk2, p38, and JNK pathways via TAK1 (4). TGF-β1 appears to promote late stage progression and metastasis in some cancers (1,2).

1.  Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.

2.  Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.

3.  Tian, M. and Schiemann, W.P. (2009) Future Oncol 5, 259-71.

4.  Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.

Entrez-Gene Id 7040
Swiss-Prot Acc. P01137

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Human Transforming Growth Factor β1 (hTGF-β1)